Ardens Lifescience Wins MedTech Innovator Asia Pacific 2026 Grand Prize for Lung Cancer Treatment Technology
Company Receives $175,000 Award for Its Minimally Invasive Radiofrequency Ablation System
MedTech Innovator, the world’s largest accelerator of medical device, digital health, and diagnostic companies, has named Ardens Lifescience the 2026 MedTech Innovator Asia Pacific Grand Prize Winner. The company received a cash award of $175,000 for its transbronchial radiofrequency (RF) ablation system, which features a conforming electrode designed to treat peripheral lung cancer.
The announcement was made during the MedTech Innovator Asia Pacific Showcase and Grand Finals in Singapore. The event brought together medical technology innovators, healthcare industry leaders, investors, corporate executives, and other stakeholders to recognize promising healthcare technologies and their potential to address unmet medical needs.
Ardens Lifescience emerged as the winner after competing against three other finalists: BaiYi Healthcare Technology, Eyes of AI, and Physiologas Technology. Following presentations from the finalists and a live question-and-answer session with a panel of medical technology executives, the audience selected Ardens Lifescience for the top honor. Each of the three runners-up received $10,000.
The recognition highlights the growing importance of medical technology innovation in improving treatment options, advancing minimally invasive procedures, and addressing complex healthcare challenges. Ardens Lifescience’s technology focuses on peripheral lung cancer, an area where precise tumor targeting and preservation of surrounding healthy lung tissue are important considerations in treatment planning.
Ardens Lifescience Advances a New Approach to Peripheral Lung Cancer Treatment
Ardens Lifescience received the Grand Prize for its transbronchial RF ablation system, which incorporates a conforming electrode intended to support the treatment of peripheral lung cancer. The technology, named CAROL, is being developed with the goal of providing a less invasive treatment option for patients with lung cancer.
Radiofrequency ablation uses electrical energy to generate heat and destroy targeted tissue. In cancer treatment, the approach can be used to damage tumor cells while limiting effects on nearby structures. The suitability of any ablation procedure depends on factors such as tumor location, size, accessibility, and the patient’s overall clinical condition.
The transbronchial approach is designed to access lung tissue through the bronchial airways. This offers a potential alternative to treatment approaches that require more invasive access to the lungs. The conforming electrode is a central component of Ardens Lifescience’s system, with the technology intended to adapt to the target area and support more precise energy delivery.
Peripheral lung cancer refers to tumors located in the outer regions of the lungs, away from the central airways. Treating tumors in these locations can present technical challenges, particularly when physicians seek to reach the target accurately while protecting surrounding lung tissue.
As diagnostic technologies and screening programs improve the identification of lung abnormalities, healthcare professionals are increasingly focused on expanding treatment options for patients diagnosed at earlier stages. Minimally invasive technologies may offer additional approaches for selected patients, depending on their diagnosis and the clinical evidence supporting each treatment.
Ardens Lifescience is seeking to contribute to this area through CAROL. The company’s recognition at the MedTech Innovator Asia Pacific Grand Finals places its technology among the innovations attracting attention from the regional and international medical technology community.
The award represents recognition of the company’s development efforts, but further clinical evaluation, regulatory requirements, and commercialization milestones remain important considerations for determining how and when the technology may become available to patients in different markets.
Leadership Highlights Mission to Expand Treatment Options
Alex Park, CEO of Ardens Lifescience, said the company was honored to receive the 2026 Grand Prize and described the recognition as an important milestone for the team.
Park attributed the win to the audience’s support for the company’s mission to develop more effective and less invasive treatment options for people living with lung cancer. He said the recognition strengthened the team’s sense of responsibility to move the technology forward and work toward making CAROL available internationally.
The company aims to accelerate its efforts to bring the system to patients, with the broader objective of offering new possibilities for lung cancer treatment. Park emphasized that the award reinforces the importance of the team’s work and its commitment to addressing the needs of people affected by the disease.
For emerging medical technology companies, recognition from an accelerator can provide visibility among potential partners, investors, healthcare providers, and industry stakeholders. It can also help companies communicate their technology’s purpose and development objectives to a broader audience.
Ardens Lifescience’s win provides a platform for further engagement with the medical technology ecosystem as the company continues its development and commercialization efforts.
MedTech Innovator Recognizes the Potential of Conforming RF Ablation
Paul Grand, founder and CEO of MedTech Innovator, congratulated Ardens Lifescience on winning the Asia Pacific Grand Prize.
Grand noted that the company’s conforming radiofrequency ablation technology is addressing important challenges associated with treating peripheral lung cancer. He highlighted the potential for the technology to support precise tumor targeting while helping preserve healthy lung tissue.
He also pointed to the opportunities emerging from earlier cancer detection. As screening and diagnostic approaches identify more patients who may benefit from timely intervention, medical technology companies have opportunities to develop treatment methods that are less invasive and suited to different clinical situations.
Grand said innovations such as CAROL could contribute to expanding the treatment options available to patients. The recognition reflects MedTech Innovator’s broader focus on identifying technologies that could address unmet needs and support advances in patient care.
However, the potential benefits of a new medical technology must ultimately be assessed through appropriate clinical evidence and regulatory review. Its adoption will depend on demonstrating safety and effectiveness, establishing a suitable role in clinical practice, and meeting the requirements of the markets in which it is introduced.
Four-Month Accelerator Program Supports 20 Medical Technology Companies
The 2026 Grand Finals marked the conclusion of MedTech Innovator Asia Pacific’s four-month accelerator program. The program brought together 20 medical technology companies selected from more than 680 applications submitted from across the Asia Pacific region and beyond.
The participating companies represented a wide range of healthcare innovation areas, including medical devices, diagnostic technologies, digital health, artificial intelligence, surgical solutions, and other emerging fields. Their work reflects the diversity of challenges being addressed by healthcare innovators, from improving diagnostic capabilities and clinical workflows to developing new treatment technologies.
The selection process provided a competitive entry point for companies seeking access to mentorship, industry expertise, and potential commercial partnerships. By bringing together innovators at different stages of development, the accelerator created opportunities for participants to present their work, receive guidance, and connect with stakeholders who understand the challenges of introducing new technologies into healthcare systems.
Developing a medical technology requires more than engineering and product design. Companies must also consider clinical validation, regulatory strategy, manufacturing readiness, reimbursement pathways, procurement processes, and the practical requirements of healthcare delivery.
These factors can be particularly challenging for early-stage companies seeking to expand beyond their home markets. The accelerator’s focus on mentorship and industry engagement is intended to help participants understand these requirements and develop strategies for advancing their technologies.
The Grand Finals provided a concluding platform for selected companies to demonstrate their solutions and communicate their value propositions. The presentations and live question-and-answer session also gave the audience an opportunity to consider the technologies’ potential relevance to healthcare needs and industry priorities.
Ardens Lifescience’s selection as the Grand Prize Winner followed this process, while the three other finalists also received financial recognition for reaching the final stage of the competition.
Industry Experts Participate in Grand Finals Judging
The 2026 Grand Finals judging panel included senior representatives from major healthcare and medical technology organizations.
The panel featured Aditya Vaidya, General Manager, Asia Pacific – Heart Recovery, at Johnson & Johnson; Santosh Nair, Head of Data & AI Portfolio at Siemens Healthineers; and Esther Kong, Manager, Innovation Research at B. Braun Medical Industries.
Their participation brought perspectives from established organizations working across healthcare technologies, medical devices, data and artificial intelligence, and clinical innovation.
Industry experts can play an important role in helping emerging companies understand the expectations of potential commercial partners and healthcare customers. Their experience can offer insight into product development priorities, market access challenges, business strategy, and the practical considerations involved in bringing a medical innovation into clinical settings.
For companies participating in an accelerator, engagement with experienced industry professionals may also help identify opportunities for collaboration and highlight areas requiring additional development.
The Grand Finals therefore served not only as a competition but also as a forum for interaction between emerging innovators and established organizations within the healthcare ecosystem.
Additional Awards Recognize Innovation Across the Cohort
Alongside the Grand Prize and runner-up awards, MedTech Innovator Asia Pacific presented several additional honors recognizing companies for achievements in areas including regional innovation support, cybersecurity, regulatory development, and communications.
EnterpriseSG STARTUP SG Grant
BaiYi Healthcare Technology from China received the EnterpriseSG STARTUP SG Grant, valued at SGD 50,000.
The award provides additional recognition for the company within the 2026 cohort. Its inclusion among the program’s award recipients reflects the range of companies participating in the accelerator and the different areas of support available to medical technology innovators.
Blue Goat Cyber Cybersecurity Award
Japan-based mediVR Inc. received the Blue Goat Cyber Cybersecurity Award, valued at $25,000.
Cybersecurity is an increasingly important consideration for medical technology companies, particularly those developing connected devices, digital health platforms, and technologies that handle sensitive patient information. Medical technology developers must consider data protection and system security alongside usability, clinical performance, and regulatory requirements.
Recognition through a cybersecurity-focused award highlights the relevance of these issues to the development and adoption of healthcare technologies.
Dovetail Regulatory Award
Lumino Medison of South Korea received the Dovetail Regulatory Award, valued at $25,000.
Regulatory planning is a key part of medical technology development. Companies must determine which requirements apply to their products, generate appropriate evidence, prepare documentation, and establish processes that support compliance in their target markets.
For companies pursuing international expansion, regulatory requirements can vary between countries and regions. Early attention to regulatory strategy can help organizations prepare for the steps involved in bringing a product to market.
Best Video Competition Award
Ardens Lifescience also received the Best Video Competition Award, valued at $5,000.
The additional recognition gives the company a second award from the 2026 program, supplementing its $175,000 Grand Prize. Clear communication is an important element of healthcare innovation, as companies must explain complex technologies to clinicians, investors, commercial partners, and other audiences.
The video award recognizes Ardens Lifescience’s work in presenting its innovation to the accelerator community.
Mentorship and Partnerships Support Commercialization
Throughout the four-month accelerator, participating companies received tailored mentorship, strategic guidance, and opportunities to engage with medical technology corporations, investors, healthcare stakeholders, and industry experts.
The program is designed to help innovators build the relationships and capabilities needed to move from technology development toward clinical adoption and commercial growth. Access to experienced mentors can help companies evaluate their business models, understand market requirements, and identify potential partners.
For medical technology developers, commercialization often involves navigating a complex network of stakeholders. These can include hospitals, clinicians, distributors, manufacturers, regulatory authorities, payers, investors, and health systems. Each group may have different expectations concerning product performance, affordability, implementation, and evidence.
Accelerator programs can help companies better understand these expectations and develop plans for addressing them. They can also create opportunities for companies to connect with organizations that may support product development, distribution, manufacturing, or market entry.
Through its global network, MedTech Innovator connects participating companies with expertise and resources intended to support clinical development, commercialization, and international expansion.
For Ardens Lifescience, the Grand Prize provides additional visibility as it works toward advancing CAROL. The company’s next steps will depend on its development priorities, the evidence required to support the technology, applicable regulatory processes, and its strategy for entering target markets.
MedTech Innovator Asia Pacific Strengthens Regional Innovation
Now in its eighth year, MedTech Innovator Asia Pacific has established a regional platform for identifying and supporting promising medical technology companies.
The program seeks to encourage collaboration across the healthcare ecosystem by connecting emerging innovators with experienced industry participants and potential strategic partners. Its international network also provides a channel through which companies can explore opportunities beyond their domestic markets.
Asia Pacific includes healthcare markets with varied regulatory systems, clinical needs, infrastructure, and adoption pathways. For innovators seeking to expand across the region, understanding these differences is essential. Partnerships with established organizations and engagement with local stakeholders can help companies assess market requirements and build appropriate commercialization strategies.
The accelerator’s focus on medical devices, diagnostics, digital health, artificial intelligence, and surgical technologies reflects the broad scope of innovation shaping modern healthcare. These technologies may support improvements in disease detection, clinical decision-making, treatment delivery, patient monitoring, and healthcare operations.
At the same time, successful adoption requires careful evaluation of clinical value, safety, cost, workflow integration, and the needs of patients and providers. Programs that bring innovators and healthcare stakeholders together can help companies explore these issues at an earlier stage.
MedTech Innovator Asia Pacific’s 2026 cohort illustrates the variety of approaches being developed to address healthcare challenges. Ardens Lifescience’s selection as Grand Prize Winner places its peripheral lung cancer treatment technology among the innovations recognized by the program this year.
Corporate Partners Support the 2026 Program
The 2026 MedTech Innovator Asia Pacific program was supported by Johnson & Johnson, B. Braun Medical Industries, Siemens Healthineers, Blue Goat Cyber, Dovetail, Cambridge Consultants, and The Mullings Group. Enterprise Singapore also joined as a 2026 partner, supporting regional expansion and innovation initiatives.
These partnerships bring together organizations with experience across medical technology, healthcare innovation, cybersecurity, regulatory support, consulting, talent, and business development.
Corporate participation can help emerging companies gain exposure to industry perspectives and understand the capabilities required to develop, validate, and commercialize healthcare products. It can also create opportunities for dialogue between innovators and organizations that operate within established healthcare markets.
For accelerator participants, such engagement can be valuable as they evaluate the technical, clinical, operational, and commercial considerations involved in scaling their businesses.
The program’s partners and mentors contribute to an environment in which medical technology companies can present their solutions, receive feedback, and explore potential paths toward growth.
Ardens Lifescience’s selection as the 2026 MedTech Innovator Asia Pacific Grand Prize Winner marks a significant milestone for the company and its efforts to develop CAROL, a transbronchial radiofrequency ablation system for peripheral lung cancer.
The $175,000 award and the additional $5,000 Best Video Competition Award recognize the company’s performance in the program and provide further visibility for its technology. The broader accelerator has also highlighted the work of other innovators through runner-up prizes and specialist awards covering grants, cybersecurity, and regulatory development.
As Ardens Lifescience works toward its goal of bringing CAROL to international markets, clinical evidence, regulatory progress, and commercialization planning will remain important factors in determining the technology’s future role in patient care.
The 2026 Grand Finals also underscore the role of accelerator programs in connecting emerging medical technology companies with industry expertise, potential partners, and resources. By supporting innovators across multiple healthcare disciplines, MedTech Innovator Asia Pacific aims to help promising technologies advance toward real-world application.
For the medical technology sector, the program’s latest cohort demonstrates continued activity across treatment innovation, diagnostics, digital health, and other emerging fields. The recognition of Ardens Lifescience highlights the ongoing effort to develop treatment approaches that may expand options for patients while addressing the clinical and practical challenges of modern healthcare.
Source link: https://www.businesswire.com/
